NASDAQ · SABS
Healthcare · Biotechnology
$3.23
Up+$0.03 (+0.94%)
Updated Oct 30, 2026, 8:07 AM
SID Score
2.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · SABS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
SABS closed at $3.23 after 21 trading sessions, up 5.56% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $3.23 | $3.36 | $3.16 | $3.23 | 458.27K |
| Oct 28, 2026 | $3.04 | $3.22 | $3.01 | $3.20 | 347.83K |
| Oct 27, 2026 | $2.80 | $3.09 | $2.80 | $3.07 | 646.57K |
| Oct 26, 2026 | $2.82 | $2.94 | $2.765 | $2.79 | 324.52K |
| Oct 23, 2026 | $2.98 | $3.04 | $2.82 | $2.84 | 1.02M |
| Oct 22, 2026 | $2.83 | $3.08 | $2.83 | $3.04 | 710.22K |
| Oct 21, 2026 | $2.88 | $2.99 | $2.795 | $2.82 | 388.77K |
| Oct 20, 2026 | $2.59 | $2.93 | $2.5537 | $2.88 | 814.54K |
| Oct 19, 2026 | $2.53 | $2.645 | $2.44 | $2.60 | 602.33K |
| Oct 16, 2026 | $2.59 | $2.63 | $2.47 | $2.53 | 756.99K |
| Oct 15, 2026 | $2.51 | $2.6197 | $2.48 | $2.59 | 787.94K |
| Oct 14, 2026 | $2.64 | $2.72 | $2.45 | $2.49 | 853.18K |
| Oct 13, 2026 | $2.84 | $2.875 | $2.615 | $2.68 | 893.5K |
| Oct 12, 2026 | $2.99 | $3.00 | $2.80 | $2.83 | 359.06K |
| Oct 9, 2026 | $2.905 | $3.02 | $2.81 | $2.98 | 659.61K |
| Oct 8, 2026 | $2.85 | $2.93 | $2.76 | $2.89 | 1.14M |
| Oct 7, 2026 | $2.90 | $2.965 | $2.81 | $2.88 | 681.68K |
| Oct 6, 2026 | $3.12 | $3.16 | $2.915 | $2.93 | 663.65K |
| Oct 5, 2026 | $3.00 | $3.25 | $2.855 | $3.10 | 866.27K |
| Oct 2, 2026 | $3.10 | $3.12 | $2.96 | $2.98 | 416.32K |
| Oct 1, 2026 | $3.15 | $3.225 | $3.04 | $3.06 | 426.59K |
The latest Smart Investors Daily articles mentioning SABS.
Company
Market Activity
Research & News
SABS research
Company profile and research snapshot.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 24, 2026 | Barclays | Overweight | — |
| Jun 17, 2026 | Chardan Capital | Buy | — |
| Jun 15, 2026 | Leerink Partners | Outperform | — |
| Jun 15, 2026 | HC Wainwright & Co. | Buy | — |
| May 22, 2026 | Citigroup | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 7, 2026
Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a fully human
globenewswire.com · Dec 8, 2025
MIAMI, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give several oral presentations at the 2nd Asian Conference on Innovative Therapies for Diabetes Management (ATTD-Asia) being held December 9-11, 2025, in Singapore.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SABS.
